



## CURRICULUM VITAE

Wojciech Jan JURCZAK

### Personal data:

DOB : 9<sup>th</sup> Aug 1966 in Kraków, Poland  
Marital status: married, 2 children  
Medical License No.: 8471647

### Work Address:

**Chair of Department of Hematology ,  
Jagiellonian University Medical College, Kopernika 17, 31-501 Kraków**

Department of Hematology, University Hospital, Kopernika 17, 31-501 Kraków,  
MCM Research Medical Center, Rejtana 2, 30-510 Kraków, Poland

### Home Address:

Kolarczyków 4, 30-225 Kraków, Poland

### Contact:

ph: (+48) 602 33 82 90, e-mail: [wojciech.jurczak@uj.edu.pl](mailto:wojciech.jurczak@uj.edu.pl), [wjurczak.mcm@mp.pl](mailto:wjurczak.mcm@mp.pl)

### Education:

1984 - 1990 Academy of Medicine - Kraków  
1986 - 1988 Jagiellonian University Faculty of MathS and Theoretical Physics  
  
1993 & 1997 specialization in Internal medicine (I & II degree)  
1996 PhD thesis  
2000 specialization in hematology  
2011 assoc. professor (habilitation)  
2017 professor of medicine

### Foreign languages:

English, French, German, Russian

### Work Experience:

since 2018 Chair of Department of Hematology, Jagiellonian University  
since 1991: Dpt of Hematology, Jagiellonian University and Department of  
Haematology, University Hospital (HO, SHO, registrar, consultant,  
vice deputy, leader of Lymphoma Team)  
  
since 2007 Research Medical Center (MCM)  
1989-90 SHO locums, UCH and Middlesex Sch. of Med. (London)  
1996 Registrar, Bone Marrow Transplant Unit, UCH, London  
1994-2010 School of Medicine in English, Jagiellonian University

**Memberships:** Polish Lymphoma Research Group (PLRG) - Board Member, Chair of clinical trial Committee,  
Polish Society of Hematology and Transfusion Medicine (PTHiT), American Society of  
Hematology (ASH), American Society of Clinical Oncology (ASCO), International  
Cardiooncology Society (ICOS), European Mantle Cell Lymphoma Network (EMCLN)

### Consultant:

**EMA (European Medicines Agency)**

Roche, Sandoz Novartis, Celtrion, Celgene, Janssen, Pharmacyclics, Acerta, Gilead, TG  
Therapeutics, Mundipharma, Spectrum, Novo Nanovector;

## Professional Interest:

- Introducing new standards in lymphoma therapy: organizing lymphoma treatment in Małopolska region (about 300 new cases annually) and arranging further medical education for practicing haematologists;
- Charring the PLRG Committee of clinical trials, organizing and coordinating national multicenter trials in Poland, special interest in MCL;
- The role of autologous and allogeneic transplant procedures and CAR-T cell therapies in lymphoma patients;
- Performing clinical trials in lymphoma patients, co-author of research papers leading to registration of Ibrutinib, Idelalisib, Belinostat, Tamsirolimus, Lenalidomide, Brentuximab and Rituximab biosimilar (National coordinator of 21 clinical trial, Principle Investigator of further 62);
- Determining the clinical role of monoclonal antibodies (Rituximab, Alectuzumab, Obinutuzumab, Brentuximab, anti- CD19 -MOR208 MoAbs); developing Rituximab biosimilars, bispecific monoclonal antibodies and radioimmunotherapy (Ibritumomab, Betalutin);
- Clinical research with drugs interacting with BCR pathway: Bruton kinase inhibitors (Ibrutinib, Acalabrutinib, Merck M7583, Beigene BGB-311) and IP3K inhibitors (Idelalisib, Copansliib, Icyte INCB050465, TGR1202);
- Immunomodulative approach in lymphoma patients: lenalidoide and checkpoint inhibitors;
- Determining the role of anthracycline cardiotoxicity, seeking alternative cytostatics (Pixanthrone);
- Investigating the role for liposomal drugs in oncology (Depocyte, Myocyte).

Personal Interests: Marathon running, hiking, mountain climbing



Wojciech Jurczak  
Kraków 28 September 2018

## Abbreviated list of 30 most important publications (IF > 650, h-index 20, citations > 3000) :

1. [Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.](#) Jurczak W, Chojnowski K, Mayer J, Krawczyk K, Jamieson BD, Tian W, Allen LF. [Br J Haematol.](#) 2018 Sep 7. doi: 10.1111/bjh.15573. [Epub ahead of print]
2. [Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.](#) Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, Salles G. [J Clin Oncol.](#) 2018 May 31;JCO2017768853.
3. [Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.](#) Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG. [J Clin Oncol.](#) 2018 May 1;JCO2017766840. doi: 10.1200/JCO.2017.76.6840. [Epub ahead of print]
4. [Ibrutinib versus tamsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.](#) Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M. [Leukemia.](#) 2018 Feb 2. doi: 10.1038/s41375-018-0023-2. [Epub ahead of print] No abstract available.
5. [Phase IIIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.](#) Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S, Winderlich M, Dirnberger-Hertweck M, Korolkiewicz R, Blum KA. [Ann Oncol.](#) 2018 May 1;29(5):1266-1272. doi: 10.1093/annonc/mdy056
6. [Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.](#) Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHOLON-1 Study Group. [N Engl J Med.](#) 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10
7. [Acalabrutinib in relapsed or refractory mantle cell lymphoma \(ACE-LY-004\): a single-arm, multicentre, phase 2 trial.](#) Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. [Lancet.](#) 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11.
8. [Comparison of two doses of intravenous tamsirolimus in patients with relapsed/refractory mantle cell lymphoma.](#) Jurczak W, Ramanathan S, Giri P, Romano A, Mocikova H, Clancy J, Lechuga M, Casey M, Boni J, Giza A, Hess G. [Leuk Lymphoma.](#) 2017 Aug 3:1-9. doi: 10.1080/10428194.2017.1357175.
9. [Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma \(ASSIST-FL\): primary results from a confirmatory phase 3, double-blind, randomised, controlled study.](#) Jurczak W, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, Castro N, Pereira J, Akria L, Alexeev S, Osmanov E, Zhu P, Alexandrova S, Zubel A, Harlin O, Amersdorffer J. [Lancet Haematol.](#) 2017 Aug;4(8):e350-e361. doi: 10.1016/S2352-3026(17)30106-0. Epub 2017 Jul 14.
10. [Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.](#) Kim WS, Buske C, Ogura M, Jurczak W, Sancho JM,

- Zhavrid E, Kim JS, Hernández-Rivas JÁ, Prokharou A, Vasilica M, Nagarkar R, Osmanov D, Kwak LW, Lee SJ, Lee SY, Bae YJ, Coiffier B. *Lancet Haematol.* 2017 Aug;4(8):e362-e373. doi: 10.1016/S2352-3026(17)30120-5. Epub 2017 Jul 14.
11. [Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders.](#) Szmít S, **Jurczak W**, Zaucha JM, Długosz-Danecka M, Sosnowska-Pasiarska B, Chmielowska E, Joks M, Drozd-Sokołowska J, Knopińska-Postuszny W, Spychałowicz W, Kumiega B, Charliński G, Morawska M, Stomian G. *Int J Cardiol.* 2017 May 15;235:147-153. doi: 10.1016/j.ijcard.2017.02.073. Epub 2017 Feb 22.
  12. [Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.](#) Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, **Jurczak W**, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. *Lancet Oncol.* 2017 Mar;18(3):297-311. doi: 10.1016/S1470-2045(16)30671-4.
  13. [Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.](#) Wu C, de Miranda NF, Chen L, Wasik AM, Mansouri L, **Jurczak W**, Galazka K, Długosz-Danecka M, Machaczka M, Zhang H, Peng R, Morin RD, Rosenquist R, Sander B, Pan-Hammarström Q. *Oncotarget.* 2016 Jun 21;7(25):38180-38190. doi: 10.18632/oncotarget.9500.
  14. [Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.](#) Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, **Jurczak W**, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. *Lancet Oncol.* 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10.
  15. [Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma \(MCL-002; SPRINT\): a phase 2, randomised, multicentre trial.](#) Trněný M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, **Jurczak W**, Morschhauser F, Alexeeva J, Rule S, Afanasyev B, Kaplanov K, Thyss A, Kuzmin A, Voloshin S, Kuliczowski K, Giza A, Milpied N, Stelitano C, Marks R, Trümper L, Biyukov T, Patturajan M, Bravo ML, Arcaini L; SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network. *Lancet Oncol.* 2016 Mar;17(3):319-31. doi: 10.1016/S1470-2045(15)00559-8. Epub 2016 Feb 16.
  16. [Postibrutinib outcomes in patients with mantle cell lymphoma.](#) Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Ibbert D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, **Jurczak W**, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA. *Blood.* 2016 Mar 24;127(12):1559-63. doi: 10.1182/blood-2015-10-673145. Epub 2016 Jan 13.
  17. [Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.](#) Dreyling M, **Jurczak W**, Jerkeman M, Silva RS, Rusconi C, Trněný M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Brückler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. *Lancet.* 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7. Erratum in: *Lancet.* 2016 Feb 20;387(10020):750.
  18. [Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.](#) **Jurczak W**, Ochrem B, Giza A, Zimowska-Curyło D, Górecki T, Boguradzki P, Knopińska-Postuszny W, Stella-Hołowiecka B, Walewski J, Joks M, Wróbel T, Zaucha JM. *Pol Arch Med Wewn.* 2015;125(10):741-8. Epub 2015 Sep 3.
  19. [Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF \(CLN-19\) Study.](#) O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduyn J, Hess G, **Jurczak W**, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A. *J Clin Oncol.* 2015 Aug 10;33(23):2492-9. doi: 10.1200/JCO.2014.59.2782. Epub 2015 Jun 22.
  20. [Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.](#) Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, **Jurczak W**, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. *Blood.* 2015 Aug 6;126(6):739-45. doi: 10.1182/blood-2015-03-635326. Epub 2015 Jun 9.
  21. [Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.](#) **Jurczak W**, Kroll-Balcerzak R, Giebel S, Machaczka M, Giza A, Ogórka T, Fornagiel S, Rybka J, Wróbel T, Kumiega B, Skotnicki AB, Komarnicki M. *Med Oncol.* 2015 Apr;32(4):90. doi: 10.1007/s12032-015-0520-3. Epub 2015 Feb 26.
  22. [PI3K \$\delta\$  inhibition by idelalisib in patients with relapsed indolent lymphoma.](#) Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, **Jurczak W**, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. *N Engl J Med.* 2014 Mar 13;370(11):1008-18. doi: 10.1056/NEJMoa1314583. Epub 2014 Jan 22.
  23. [Premature cardiovascular mortality in lymphoma patients treated with \(R\)-CHOP regimen - a national multicenter study.](#) **Jurczak W**, Szmít S, Sobociński M, Machaczka M, Drozd-Sokołowska J, Joks M, Dzięczenia J, Wróbel T, Kumiega B, Zaucha JM, Knopińska-Postuszny W, Spychałowicz W, Prochwicz A, Drohomirecka A, Skotnicki AB. *Int J Cardiol.* 2013 Oct 15;168(6):5212-7. doi: 10.1016/j.ijcard.2013.08.033. Epub 2013 Aug 15.
  24. [Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.](#) Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, **Jurczak W**, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McCreivry J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. *N Engl J Med.* 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19.
  25. [Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the International Radioimmunotherapy Network.](#) Hohloch K., Delaloye A. B., Windemuth-Kieselbach C., Gomez-Codina J., Linkesch W., **Jurczak W**., Cacchione R., Suh C., Zinzani P. L. i Trümper L. *Nucl Med.* 2011 Sep;52(9):1354-60. doi: 10.2967/jnumed.111.089920. Epub 2011 Aug 9.
  26. [\[Post transplant lymphoproliferative disorder \(PTLD\)--10 years follow-up\].](#) Ignacak E, Betkowska-Prokop A, Kuźniewski M, Rudzki Z, Okoń K, Skotnicki A, **Jurczak W**, Kulig J, Czupryna A, Bucki J, Sułowicz W. *Przegl Lek.* 2011;68(12):1202-3. Polish.
  27. [Radioimmunotherapy with \(90\)Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network.](#) Hohloch K, Zinzani PL, Linkesch W, **Jurczak W**, Deptala A, Lorsbach M, Windemuth-Kieselbach C, Wulf GG, Truemper LH. *Bone Marrow Transplant.* 2011 Jun;46(6):901-3. doi: 10.1038/bmt.2010.202. Epub 2010 Sep 27.
  28. [High prevalence of non-Hodgkin's lymphomas in Polish population--1106 new cases diagnosed according to WHO classification in only one district.](#) **Jurczak W**, Rudzki Z, Gałazka K, Gruchała A, Jaszcz-Gruchała A, Skotnicki AB, Stachura J. *Pol J Pathol.* 2006;57(1):45-52.
  29. [ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.](#) Rudzki Z, Rucińska M, **Jurczak W**, Skotnicki AB, Maramorosz-Kurianowicz M, Mruk A, Piróg K, Utych G, Bodzioch P, Srebro-Stariczek M, Włodarska I, Stachura J. *Pol J Pathol.* 2005;56(1):37-45.
  30. [Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients.](#) Czyz J, Dziadziuszko R, Knopińska-Postuszny W, Hellmann A, Kachel L, Holowiecki J, Gozdziak J, Hansz J, Avigdor A, Nagler A, Osowiecki M, Walewski J, Mensah P, **Jurczak W**, Skotnicki A, Sedzimirka M, Lange A, Sawicki W, Sulek K, Wach M, Dmoszynska A, Kus A, Robak T, Warzocha K. *Ann Oncol.* 2004 Aug;15(8):1222-30.